Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Return on Capital Employed: 2021-2025

Historic Return on Capital Employed for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Sep 2025 value amounting to -0.55%.

  • Rhythm Pharmaceuticals' Return on Capital Employed rose 41.00% to -0.55% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.55%, marking a year-over-year increase of 41.00%. This contributed to the annual value of -1.07% for FY2024, which is 47.00% down from last year.
  • As of Q3 2025, Rhythm Pharmaceuticals' Return on Capital Employed stood at -0.55%, which was up 21.73% from -0.71% recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Return on Capital Employed ranged from a high of -0.37% in Q2 2021 and a low of -1.12% during Q1 2024.
  • Moreover, its 3-year median value for Return on Capital Employed was -0.66% (2023), whereas its average is -0.77%.
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Return on Capital Employed tumbled by 56bps in 2024, and later surged by 50bps in 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Return on Capital Employed (Quarterly) stood at -0.57% in 2021, then grew by 5bps to -0.52% in 2022, then dropped by 12bps to -0.64% in 2023, then plummeted by 37bps to -1.01% in 2024, then soared by 41bps to -0.55% in 2025.
  • Its Return on Capital Employed stands at -0.55% for Q3 2025, versus -0.71% for Q2 2025 and -0.62% for Q1 2025.